HomeClinical TopicsFDA approves new drug for metastatic lung cancer

FDA approves new drug for metastatic lung cancer

On Oct. 9, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to treat patients with metastatic non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content